Genetic polymorphisms of rs9949644 in MAPK4 are associated with clinical response to methotrexate in patients with psoriasis.

Fan, Zhijia; Huang, Qiong; Zhang, Zhenghua; Han, Ling; Fang, Xu; Yang, Ke; Huang, Guiqin; Zheng, Zhizhong; Yawalkar, Nikhil; Lin, Yong; Wang, Zhicheng; Yan, Kexiang (2024). Genetic polymorphisms of rs9949644 in MAPK4 are associated with clinical response to methotrexate in patients with psoriasis. Dermatology, 240(1), pp. 111-118. Karger 10.1159/000533260

[img] Text
000533260.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (362kB) | Request a copy

Background The study aimed to investigate the relationship of MAPK4 genetic variants with the efficacy of MTX in psoriasis patients. Methods Patients treated with MTX were classified as responders or nonresponders if the Psoriasis Area and Severity Index (PASI) at week 12 was reduced to greater than 75% or lower than 75%, respectively. The genotypes of 14 MAPK4 single nucleotide polymorphisms (SNPs) in 310 patients were analyzed. The expression levels of MAPK4 protein were detected by western blot. Results Only rs9949644 polymorphisms were associated with the efficacy after adjusting for the confounding factors. Patients with the rs9949644 AG or GG genotype had a better clinical response compared to patients with the AA genotype. Rs9949644 polymorphisms were significantly associated with the PASI improvement rate. Besides, the protein level of MAPK4, positively associated with the psoriasis severity, was higher in patients. There were no significant differences of MAPK4 protein levels among three groups. While after treatment, MAPK4 levels in the AG or GG group showed a significantly down-regulated trend. Conclusions By demonstrating the significant association of MAPK4 with the efficacy of MTX, this study indicates that MAPK4 may be involved in the psoriasis progression and act as a predictor of therapeutic response.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Yawalkar, Nikhil

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1421-9832

Publisher:

Karger

Language:

English

Submitter:

Andrea Studer-Gauch

Date Deposited:

28 Nov 2023 16:00

Last Modified:

14 Feb 2024 00:14

Publisher DOI:

10.1159/000533260

PubMed ID:

37494889

BORIS DOI:

10.48350/189468

URI:

https://boris.unibe.ch/id/eprint/189468

Actions (login required)

Edit item Edit item
Provide Feedback